DE69733960D1 - Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation - Google Patents

Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation

Info

Publication number
DE69733960D1
DE69733960D1 DE69733960T DE69733960T DE69733960D1 DE 69733960 D1 DE69733960 D1 DE 69733960D1 DE 69733960 T DE69733960 T DE 69733960T DE 69733960 T DE69733960 T DE 69733960T DE 69733960 D1 DE69733960 D1 DE 69733960D1
Authority
DE
Germany
Prior art keywords
antibodies
immunomodulation
leukocyte antigen
cd45ro
cd45ro leukocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69733960T
Other languages
English (en)
Other versions
DE69733960T2 (de
Inventor
I Lazarovits
Sibrand Poppema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALIMMUNE L.L.C., TUCSON, ARIZ., US
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Publication of DE69733960D1 publication Critical patent/DE69733960D1/de
Application granted granted Critical
Publication of DE69733960T2 publication Critical patent/DE69733960T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69733960T 1996-09-18 1997-09-17 Verwendung von Antikörpern gegen CD45RO Leukozytenantigen zur Immunmodulation Expired - Fee Related DE69733960T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US715342 1996-09-18
US08/715,342 US6106834A (en) 1993-06-02 1996-09-18 Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
PCT/US1997/016321 WO1998011918A1 (en) 1996-09-18 1997-09-17 Use of antibodies to cd45r leukocyte antigens for immunomodulation

Publications (2)

Publication Number Publication Date
DE69733960D1 true DE69733960D1 (de) 2005-09-15
DE69733960T2 DE69733960T2 (de) 2006-05-24

Family

ID=24873646

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733960T Expired - Fee Related DE69733960T2 (de) 1996-09-18 1997-09-17 Verwendung von Antikörpern gegen CD45RO Leukozytenantigen zur Immunmodulation

Country Status (8)

Country Link
US (3) US6106834A (de)
EP (1) EP0939652B1 (de)
JP (1) JP2001501607A (de)
AT (1) ATE301471T1 (de)
CA (1) CA2266684A1 (de)
DE (1) DE69733960T2 (de)
ES (1) ES2247638T3 (de)
WO (1) WO1998011918A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7014998B2 (en) 2000-09-30 2006-03-21 Yale University Screening immunomodulatory agents by CTLA-4 upregulation
US20050069538A1 (en) * 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds
JP2005536180A (ja) * 2001-12-03 2005-12-02 アブジェニックス・インコーポレーテッド 自己免疫疾患の治療および移植拒絶の処置に使用する抗ｃｄ４５ｒｂ抗体
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
WO2003061695A1 (en) * 2002-01-17 2003-07-31 Amgen Inc. Methods of regulating cytokine receptor signaling
BR0312484A (pt) * 2002-07-01 2008-01-08 Savient Pharmaceuticals Inc compostos e métodos para tratamento terapêutico
US20040146503A1 (en) * 2002-08-28 2004-07-29 Tesi Raymond J. Methods and compositions for inducing stable immune tolerance
US20040047858A1 (en) * 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
WO2005018668A1 (en) * 2003-08-25 2005-03-03 Pangenetics B.V. Method of inducing immune tolerance
DE602004026081D1 (de) * 2003-09-18 2010-04-29 Novartis Ag Therapeutische humanisierte antikörper gegen cd45-isoformen
US20080003224A1 (en) * 2006-01-27 2008-01-03 Cellerant Therapeutics, Inc. Compositions and methods for treating haematological proliferative disorders
WO2007140457A2 (en) * 2006-05-31 2007-12-06 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
EP2051987B1 (de) 2006-08-18 2014-11-19 Argos Therapeutics, Inc. Verwendung von cb83 in kombinationstherapien
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
KR101323540B1 (ko) 2007-02-07 2013-10-29 사이단호진한다이비세이부쯔뵤우겐큐우카이 암의 치료제
WO2013021784A1 (ja) * 2011-08-10 2013-02-14 ナパジェン ファーマ，インコーポレテッド 免疫寛容誘導剤
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
US9713636B2 (en) 2011-02-28 2017-07-25 Napajen Pharma, Inc. Nucleic acid/polysaccharide complex
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US20170226209A1 (en) * 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
EP3858388B1 (de) 2015-09-28 2024-07-03 Regents of the University of Minnesota T-zellen mit chimärem antigenrezeptor (car) als therapeutische eingriffe bei gvhd
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
IL303455A (en) 2016-06-17 2023-08-01 Crispr Therapeutics Ag Compositions and methods for depleting CD117 plus cells
CA3028145A1 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
WO2018085617A1 (en) 2016-11-07 2018-05-11 Argos Therapeutics, Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
EP3917313A4 (de) * 2019-02-01 2023-02-08 Actinium Pharmaceuticals, Inc. Gegen cd45 gerichtete moleküle und deren derivate
CN111707833A (zh) * 2020-06-19 2020-09-25 徐州医科大学 小鼠血管内外淋巴细胞识别的方法及其应用
MX2023007384A (es) 2020-12-21 2023-07-05 Allogene Therapeutics Inc Car con puerta cd45 activado por proteasa.
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
TW202300522A (zh) 2021-03-17 2023-01-01 日商第一三共股份有限公司 編碼對抗乙醯膽鹼受體自體抗體之嵌合受體之基因
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20230399375A1 (en) 2022-04-15 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
WO2023240064A1 (en) 2022-06-08 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626507A (en) * 1980-09-25 1986-12-02 The Salk Institute For Biological Studies Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
BR9007769A (pt) * 1989-10-20 1992-08-11 Lynxvale Ltd Preparacao para o tratamento de tecido alheio,processo para a preparacao de tecido alheio ex-vivo antes de transplante ou de seu uso como material curativo,processo para o tratamento de um paciente,e,processo para realizacao de transplantes de orgaos alogenicos ou xenogenicos a um paciente humano,ou para fornecimento de curativo alogenico ou xenogenico a este paciente
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CA2110518C (en) * 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
GB9323542D0 (en) * 1993-11-15 1994-01-05 Univ Alberta Lymphocyte marker specific for corhn's disease
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US6174710B1 (en) 1994-08-09 2001-01-16 Pfizer Inc. Spirolaxine derivatives for treating gastrobuodenal diseases

Also Published As

Publication number Publication date
ATE301471T1 (de) 2005-08-15
ES2247638T3 (es) 2006-03-01
US6106834A (en) 2000-08-22
DE69733960T2 (de) 2006-05-24
WO1998011918A1 (en) 1998-03-26
US7160987B2 (en) 2007-01-09
US20020168362A1 (en) 2002-11-14
EP0939652B1 (de) 2005-08-10
EP0939652A1 (de) 1999-09-08
CA2266684A1 (en) 1998-03-26
JP2001501607A (ja) 2001-02-06
US6379668B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
DE69733960D1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE69429095D1 (de) Humanisierte antikoerper
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DE69032922D1 (de) Menschliches intra-akrosomales spermaantigen zur verwendung in einem empfängnisverhütungsimpfstoff
FI951164A (fi) Respiratory syncytial -viruksen vastaiset neutraloivat ihmisen monoklonaaliset vasta-aineet
DE69433406T2 (de) Antikörper gegen cd40
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
NO965239D0 (no) Monoklonalt antistoff mot CD44v6
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
DE59309458D1 (de) Synthetische Peptide, Antikörper dagegen und ihre Verwendung
DE3650032D1 (de) Anticytomegaloviraler menschlicher monoklonaler antikörper und dessen herstellung.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DK0537168T3 (da) Antigenet CTAA 28A32, som genkendes af MCA 28A32
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
DE69221605D1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
DE69010897D1 (de) Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ALIMMUNE L.L.C., TUCSON, ARIZ., US

8339 Ceased/non-payment of the annual fee